enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
0.3536
-0.0344 (-8.87%)
At close: Dec 5, 2025, 4:00 PM EST
0.3516
-0.0020 (-0.57%)
After-hours: Dec 5, 2025, 7:56 PM EST
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$593,649
Market Cap
7.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVNO News
- 10 days ago - enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment - Accesswire
- 23 days ago - enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve - Accesswire
- 5 weeks ago - enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment - Accesswire
- 2 months ago - enVVeno Medical Updates Regulatory Status of VenoValve(R) - Accesswire
- 3 months ago - enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) - Accesswire
- 4 months ago - enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Accesswire
- 4 months ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire